Regeneron Pharmaceuticals reported second quarter 2026 total revenues of $4.3 billion, a 17% increase year-over-year, driven by strong commercial performance. Global net sales of Dupixent reached a record $6.0 billion (up 38%), while U.S. EYLEA HD sales rose 52% to $596 million and global Libtayo sales increased 30% to $489 million. GAAP diluted EPS was $12.23, including a $1.02 negative impact from in-process research and development (IPR&D); non-GAAP diluted EPS was $14.29. The company fully repaid the Sanofi Development Balance by the end of the quarter. Regulatory submissions for cemdisiran were accepted for review by the FDA and EMA, with a target FDA action date in November 2026. Additionally, Regeneron declared a quarterly cash dividend of $0.94 per share, payable on August 31, 2026 to shareholders of record as of August 18, 2026. The company operates in the biotechnology industry, inventing and commercializing medicines for serious diseases.

Regeneron Pharmaceuticals, Inc. expects an acquired in-process research and development charge of approximately $127 million on a pre-tax basis for the second quarter of 2026. This charge, related to collaboration and licensing agreements, is expected to negatively impact GAAP and non-GAAP net income per diluted share by approximately $1.00. Regeneron is a biotechnology company that develops and manufactures biopharmaceutical products.